BioAsset

Insights / All articles

Company Analysis

The Price to Pay to End an mRNA Vaccine Fight: Up to $2.25B to be Paid by Moderna

By Jingqiu Tian, Research Analyst at BioAsset · 5 slides

Moderna has agreed to pay up to $2.25 billion to Arbutus Biopharma and Genevant Sciences, a Roivant subsidiary, in a settlement that ends the legal dispute over the technologies used in its vaccines. The sum is large, but the deal is a win for Moderna because it avoids a much worse outcome.

Moderna’s rise

Moderna is a biotechnology company founded in 2010 that works on mRNA medicines. The name incorporates “modified” and “RNA,” emphasising that focus. Success came quickly. In 2015, Moderna initiated the first-in-human dose of an mRNA vaccine candidate for H10N8 flu, and in 2019 it announced dosing of the first antibody encoded by mRNA in a clinical trial.

What brought Moderna to prominence was its development of one of the world’s first COVID vaccines. In 2022, the company received full approval from the U.S. Food and Drug Administration for Spikevax, an mRNA vaccine designed to prevent COVID-19.

Why lipid nanoparticles matter

Traditional vaccines work by injecting a weakened or inactivated virus (or a virus subunit) to prepare the immune system against the disease in advance. mRNA vaccines work by injecting mRNA wrapped in lipid nanoparticles for delivery. The body can use this mRNA to create the virus’s spike proteins, which prepares the immune system in advance.

The lipid nanoparticles are key to mRNA vaccines, because mRNA is fragile and hard to transport into the cell. Their use is also what has been causing problems for Moderna. The nanoparticles that are essential for its drugs, Spikevax among them, were pioneered by other companies, including Arbutus.

The settlement

Moderna will make an upfront payment of $950 million in the third quarter of this year. Another $1.3 billion payment may follow, depending on the outcome of Moderna’s appeal to the federal circuit court. Following this payment, Moderna will not have to pay future royalties to the two companies on its sales of mRNA vaccines.

The settlement came just before the start of a trial in which Arbutus and Genevant were seeking roughly $5 billion. In that worst-case scenario, Moderna would have had to pay roughly $5 billion and future royalties, which would have added to the company’s financial stress.

Moderna shares rose by 9% on Wednesday, reflecting its success in avoiding that scenario. A one-month price chart shows the stock at $57.80 on Mar 4, 2026.

Insights

The development of lipid nanoparticles has been a crucial breakthrough in mRNA vaccine development. Companies that hold the key technologies for developing them are now involved in suits against companies producing mRNA vaccines, and could pocket even more payments. Arbutus and Genevant, for instance, have settled with Moderna but are still in ongoing suits against Pfizer and BioNTech, which are among the other companies that developed mRNA vaccines for COVID.

For Moderna, the settlement is definitely a win. The company has been under financial stress for years, since COVID vaccine sales declined, and a larger payment with additional royalties would have left it in even more financial stress. The rise in its share price reflects a successful settlement. Moderna now expects to end the year with roughly $5 billion in cash and cash equivalents.

Moderna’s case makes one thing clear. Companies that were brought to prominence by developing mRNA COVID vaccines now face lawsuits over key technologies and financial pressure from declining COVID vaccine sales. They need to actively seek new growth drivers to cope with that stress. Moderna, for its part, is now well-funded for several of its cancer vaccine trials.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.